CRUK-OPTION, NCT00427245: Goserelin in Preventing Early Menopause in Premenopausal Women Undergoing Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer |
|
|
| Completed | 3 | 400 | Europe | cyclophosphamide, goserelin acetate, adjuvant therapy, fertility assessment and management, neoadjuvant therapy | Anglo Celtic Cooperative Oncology Group | Breast Cancer, Infertility, Menopausal Symptoms | | | | |
NCT01218581: Aromatase Inhibitors or GnRH-a for Uterine Adenomyosis |
|
|
| Completed | 2/3 | 32 | RoW | received oral letrozole (2.5 mg/day)and goserelin subcutaneosly (3.6 mg/month) | Mansoura University | the Efficacy of Aromatase Inhibitor vs. Gonadotrpins Releasing Hormone Agonists in Treating Premenopausal Women With Uterine Adenomyosis | 01/10 | 01/10 | | |
